A-protein Levels in Adult and Pediatric Brain Tumor Patients

Completed

Conditions studied: Malignant Childhood Central Nervous System Neoplasm

In brief

The purpose of this study is to evaluate the sensitivity and specificity of "A-PROTEIN" levels in patients with brain tumors. A-PROTEIN levels will be analyzed both pre and post treatment. Levels in blood and/or cerebrospinal fluid (CSF) will be analyzed and correlated with the underlying diagnosis and outcome.

Key facts

Study ID

NCT00165542

Run by

Dana-Farber Cancer Institute

People needed

54

Starts

1998-06-01

Expected to finish

2009-08-01

Last updated by the study team

2016-11-23

Who can join

Age: any, up to 77. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• All patients with possible malignant or benign lesions of the central nervous system will be included.
• There are no restrictions with respect to treatment protocols or prior therapy.
• Patients will be identified after presentation to the neurosurgical, neurological or oncologic services at participating centers. Any patient with evidence of a central nervous system tumor will be eligible. Individuals without evidence of CNS tumors are also eligible, in order to provide blinded controls.
• A signed informed consent will be requested and required for participation.
• There is no age, sex, or ethnic origin restrictions in this protocol. Patients who choose not to participate in the study will continue to have their regular care as defined by their treating team. Patients who speak foreign languages are eligible as long a translator can be found to ensure proper consent has been obtained.
• Exclusion Criteria: There are no exclusion criteria for this study.

Where it is running

• Dana Farber Cancer Institite — Boston, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.